Transforming Treatments with Cell Therapies
ERNA-101 is designed to activate and enhance the immune system's response to recognize and attack cancer cells. Our best-in-class, synthetic iMSCs represent a new class of precision-guided therapeutics, taking advantage of the MSC’s natural tumor-homing abilities to migrate directly to tumor sites, allowing them to slip through the tumor’s defenses and infiltrate tumor tissue.
The iMSCs can then deliver potent cytokines directly to the tumor microenvironment, ultimately triggering a strong immune response against the cancer cells.
Targeting Inflammation, Advancing Treatment for Autoimmune Disease
ERNA-201 is our other cell therapy product designed to target inflammation and treat autoimmune disease. By calming overactive immune cells, ERNA-201 aims to help treat autoimmune disease more effectively. With its unique mechanism of action, ability to last longer in the body, and precision-targeting to the site of inflammation, ERNA-201 represents a promising next-generation of anti-inflammatory therapy.
Current treatments for autoimmune disease are limited in their efficacy. ERNA-201 has the potential to bring significant hope to patients suffering from autoimmune disease.
Download Fact Sheet